Cotrimoxazole for CRE Pneumonia: Not Recommended as Primary Therapy
Cotrimoxazole (trimethoprim-sulfamethoxazole) should NOT be used as primary therapy for CRE pneumonia. For severe CRE pneumonia, use ceftazidime-avibactam or meropenem-vaborbactam if the organism is susceptible in vitro 1. Cotrimoxazole may only be considered for non-severe CRE infections (not pneumonia) when the isolate is susceptible and as part of antibiotic stewardship efforts to spare newer agents 1.
Why Cotrimoxazole Fails for CRE Pneumonia
Limited Susceptibility
- Only 29% of CRE isolates are susceptible to TMP-SMX 2
- Resistance develops readily during therapy, further limiting utility 2
- No guideline recommends TMP-SMX for CRE pneumonia specifically
Guideline-Directed Therapy for CRE Pneumonia
For severe CRE pneumonia:
- First-line: Ceftazidime-avibactam OR meropenem-vaborbactam (if susceptible) 1
- For metallo-β-lactamase producers: Cefiderocol OR aztreonam + ceftazidime-avibactam combination 1
- If only old antibiotics available: Use combination therapy with 2+ active agents (polymyxins, aminoglycosides, tigecycline, fosfomycin) 1
Critical caveat: Tigecycline should NOT be used for bloodstream infections or hospital-acquired/ventilator-associated pneumonia; if absolutely necessary for pneumonia, use high-dose tigecycline only 1
When Cotrimoxazole Has ANY Role in CRE
The 2022 ESCMID guidelines mention cotrimoxazole only for:
- Non-severe CRE infections (explicitly NOT pneumonia)
- Complicated urinary tract infections without septic shock 1
- Step-down therapy after stabilization with carbapenems for 3GCephRE (not CRE) 1
Dosing IF Used (Not for Pneumonia)
If cotrimoxazole were used for a susceptible non-severe CRE infection (again, not pneumonia):
- Standard dose: 15-20 mg/kg/day (trimethoprim component) divided every 6-12 hours 3
- Renal adjustment required: Reduce dose by 50% if CrCl 15-30 mL/min; avoid if <15 mL/min 3
- Duration: Typically 10-14 days for most infections 3
The Evidence Gap
- No high-quality studies support TMP-SMX for CRE pneumonia specifically
- One small case series showed success in 14 Kp-KPC infections (mostly non-pneumonia, only 3 bloodstream infections) with 71% receiving monotherapy 4
- Studies on TMP-SMX for pneumonia focus on Stenotrophomonas maltophilia or carbapenem-resistant Acinetobacter, not CRE 5, 6
- VAP de-escalation study showed TMP-SMX was safe but did not specifically address CRE 7
Practical Algorithm for CRE Pneumonia
- Obtain susceptibility testing immediately - resistance mechanisms matter
- Severe pneumonia with KPC or OXA-48 producers: Ceftazidime-avibactam or meropenem-vaborbactam
- Metallo-β-lactamase producers: Cefiderocol (if susceptible) OR aztreonam + ceftazidime-avibactam
- Pan-resistant or new agents unavailable: Polymyxin-based combination (2+ active drugs) - monitor renal function closely 8
- Never use tigecycline monotherapy for pneumonia - high-dose only if no alternatives 1
Do not use cotrimoxazole for CRE pneumonia regardless of in vitro susceptibility - inadequate lung penetration data, high resistance rates, and lack of clinical evidence make this an inappropriate choice when mortality is at stake.